| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
The level of FDG accumulation within lung cancer cells was closely associated with glucose metabolism (Glut1) and hypoxia(HIF-1). In vitro and in vivo studies, the uptake of FDG within tumor cells showed a mild change after bevacizumab monotherapy, but that markedly revealed a significant reduction after combination of paclitaxel and bevacizumab. Moreover, we had planed a clinical trial to examine the therapeutic monitoring of platinum-based regimens plus bevacizumab for patients with lung cancer. The results suggest that FDG-PET is useful tool to evaluate the treatment response after the regimens including bevacizumab in patients with lung cancer.
|
